Pfizer should have different top-selling drugs in 2030 with a heavier focus on oncology. The drugmaker should be more ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 3 clinical study titled ‘MagnetisMM-32’ ...

Pfizer Inc. continues to showcase potential practice-changing research and next-generation candidates across its robust Oncology portfolio at the European Society for Medical Oncology Congress ...

Pfizer Inc. will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology Annual Meeting, taking place May 30 to June 3 in ...

Jun. 08, 2016 1:51 PM ET Pfizer Inc. (PFE) Stock SA Transcripts 151.29K Follower s Pfizer Inc. (NYSE: PFE) Analyst and Investor Call to Review Oncology Business and ASCO Data Presentations Call ...

Pfizer Inc PFE, one of the world’s largest pharmaceutical firms, is on the verge of a bullish Golden Cross, a significant technical indicator suggesting potential upward momentum for the stock.

Photo: Mark Lennihan/Associated Press Pfizer PFE 0.74% had a problem. Doctors weren’t prescribing its migraine drug Nurtec because they assumed insurance coverage would be too much of a hassle.

Pfizer CEO Albert Bourla, under pressure from activist hedge fund Starboard Value, made his case to Wall Street on Tuesday that the drugmaker's turnaround is succeeding after it reported a higher ...

More than 60 abstracts, including 15 oral and rapid oral presentations, highlight advancements across Pfizer’s industry-leading Oncology portfolio ASCO press program to feature overall survival ...